AstraZeneca strikes $700m deal with Dublin-based Actavis

Drugs giant AstraZeneca is to boost its portfolio with the acquisition of a branded respiratory drug business for up to US $700m (€613m).
The agreement with Dublin-based rival Actavis to buy its respiratory business in North America includes the purchase of inhalation powder Tudorza Pressair, used by sufferers of chronic bronchitis.